A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Clinical trial NCT05367401 · WITHDRAWN

Trial details

NCT number: NCT05367401
Sponsor: Novartis Pharmaceuticals
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndromes Acute Myeloid Leukemia

Start date: 2024-12-20
Primary completion: 2029-10-26
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.